ArticleInternational journal of surgery case reports2026
Renal small cell neuroendocrine carcinoma: a case report and literature review.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Renal small-cell neuroendocrine carcinoma (renal SCNEC) is an exceedingly rare and highly aggressive tumor of the urinary system, originating from peptidergic neurons or neuroendocrine cells. The disease often presents with insidious clinical symptoms and lacks specific imaging features, which can delay diagnosis and predispose to distant metastases. Here, we report a case of renal SCNEC and describe its diagnosis, treatment, and outcomes, aiming to enhance clinical understanding and management of this rare condition. Case presentation: We report the case of a 64-year-old man who presented with left-sided flank pain without hematuria. Imaging studies revealed a mass in the left kidney. Percutaneous biopsy and immunohistochemical analysis confirmed the diagnosis of SCNEC. The patient received two cycles of neoadjuvant chemotherapy consisting of cisplatin and etoposide, followed by laparoscopic radical nephrectomy. Postoperative chemotherapy was administered according to the planned regimen. During 16 months of follow-up, no evidence of recurrence was observed. Discussion: Prompt recognition and diagnosis of renal SCNEC are crucial to prevent misdiagnosis and delayed treatment. Diagnosis relies on histopathology, immunohistochemistry, and careful evaluation of common metastatic sites, including lymph nodes, liver, and bones. Treatment should be individualized based on disease stage and the patient's condition; for locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may be considered as part of a multimodal treatment strategy in selected patients. Given the rarity of this tumor, multidisciplinary collaboration and evidence-based research are essential to optimize management and establish standardized treatment guidelines. Conclusion: For patients with locally advanced renal SCNEC, platinum-based chemotherapy combined with radical surgery may provide a therapeutic option after multidisciplinary evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.